Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo  >  Takeda Pharmaceutical Co Ltd    4502   JP3463000004

TAKEDA PHARMACEUTICAL CO LTD (4502)
My previous session
Most popular
  Report  
SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets

Takeda Pharmaceutical : Earnings Conference for the 2nd Quarter of Fiscal Year 2018

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/12/2018 | 03:08am CEST

Dear Investors and Analysts,

We would like to inform you that Takeda will announce its 2nd Quarter Financial Results for Fiscal Year 2018 at 3:00 pm (JST) on October 31st, 2018. From 5:30 to 7:00 pm (JST) on the same day, Takeda will hold an earnings conference at our Tokyo headquarters, which will also be accessible by telephone and internet webcast.

Time & Location:
5:30-7:00 pm (JST), Wednesday, October 31st, 2018
Takeda Tokyo Headquarters, 6F Grand Hall

Participants:
Christophe Weber, President and Chief Executive Officer
Andrew Plump, Chief Medical & Scientific Officer
Costa Saroukos, Chief Financial Officer
Takashi Okubo, Global Head of Investor Relations

Notes:

  • The related documents/presentation materials will be posted on our website from 3:00 pm (JST) on October 31st. (https://www.takeda.com/investors/reports/quarterly-announcements/quarterly-announcements-2018/)
  • Simultaneous English interpretation will be provided for the Japanese sections.
  • An audio webcast of the conference will be streamed live on the Takeda website (listening mode only). If you wish to participate in the Q&A session, please join the conference via the telephone numbers provided below.
  • The audio webcast will be available for on-demand listening shortly after the conclusion of the event.

Start Time / Dial-in / Passcode

Start Time

San Francisco (PDT)
New York, Toronto (EDT)
London (GMT)
Frankfurt, Paris (CET)
Hong Kong (HKT)
Singapore (SGT)
Tokyo (JST)
Sydney(AEDT)

1:30am (October 31)
4:30am (October 31)
8:30am (October 31)
9:30am (October 31)
4:30pm (October 31)
4:30pm (October 31)
5:30pm (October 31)
7:30pm (October 31)

Duration

Approx. 90 Minutes

Toll-free Dial-in

Australia
Canada
France
Germany
Hong Kong
Japan
Singapore
Switzerland
U.K.
U.S.A

1800-990-329
1855-369-0434
080-598-0121
0800-627-0775
800-961-330
0120-611-299
800-120-6854
0800-001-079
0800-026-1544
1855-369-0433

Direct Dial-in

+81-3-6629-1042

Passcode

60020547#

Disclaimer

Takeda Pharmaceutical Co. Ltd. published this content on 12 October 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 12 October 2018 01:07:06 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on TAKEDA PHARMACEUTICAL CO L
02:08pTAKEDA PHARMACEUTICAL : to Present Results from Phase 3 ALTA-1L Trial Highlighti..
PU
02:03pTAKEDA PHARMACEUTICAL : to Present Results from Phase 3 ALTA-1L Trial Highlighti..
BU
10/18TAKEDA PHARMACEUTICAL : Japan’s Takeda gets regulator’s approval to ..
AQ
10/18TAKEDA PHARMACEUTICAL : gets Japanese approval for $62 billion Shire purchase
RE
10/18TAKEDA PHARMACEUTICAL : Receives Clearance from the Japan Fair Trade Commission ..
BU
10/18TAKEDA PHARMACEUTICAL : receives clearance from the Japan Fair Trade Commission ..
PU
10/12TAKEDA PHARMACEUTICAL : Earnings Conference for the 2nd Quarter of Fiscal Year 2..
PU
10/06SHIRE : Disgruntled Takeda alumni demand a window into $62B Shire buy
AQ
10/04SEATTLE GENETICS : and Takeda Announce Positive Results from Phase 3 ECHELON-2 C..
AQ
10/04SEATTLE GENETICS` : Adcetris tops chemo in Phase 3 lymphoma trial
AQ
More news
News from SeekingAlpha
10/18GAMIDA IPO : Phase 3 Of Development 
10/18MARKER THERAPEUTICS : A Safer And Potentially More Effective CAR-T Alternative 
10/18Markets Under Pressure Over Future Fed Hikes (Wall Street Breakfast Podcast) 
10/18WALL STREET BREAKFAST : Fed Maintains Hawkish Tone 
10/18Takeda gets Shire clearance from Japan 
Financials (JPY)
Sales 2019 1 765 B
EBIT 2019 -
Net income 2019 162 B
Debt 2019 680 B
Yield 2019 3,83%
P/E ratio 2019 22,68
P/E ratio 2020 18,70
EV / Sales 2019 2,50x
EV / Sales 2020 2,35x
Capitalization 3 738 B
Chart TAKEDA PHARMACEUTICAL CO LTD
Duration : Period :
Takeda Pharmaceutical Co Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TAKEDA PHARMACEUTICAL CO L
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Average target price 6 267  JPY
Spread / Average Target 33%
EPS Revisions
Managers
NameTitle
Christophe Weber President, CEO & Representative Director
Costa Saroukos Chief Financial Officer
Andrew S. Plump Director, Chief Medical & Scientific Officer
Yasuhiko Yamanaka Managing Director & Head-Globalization
Masato Iwasaki Director & President-Japan Pharma Business Unit
Sector and Competitors
1st jan.Capitalization (M$)
TAKEDA PHARMACEUTICAL CO LTD-27.63%33 229
JOHNSON & JOHNSON-4.19%374 244
PFIZER20.87%257 933
NOVARTIS0.07%220 104
ROCHE HOLDING LTD.-4.56%206 610
MERCK AND COMPANY23.44%192 044